Blueprint Medicines Strengthens Leadership with Appointment of Fouad Namouni, M.D., as President, Research & Development
In his new role, Dr. Namouni will lead a joint research and development organization, overseeing all phases of product development from discovery through global registration under a unified portfolio vision, and join the executive management team.
"We are excited to welcome Fouad, a seasoned drug developer and portfolio strategist, to broaden our ambitious R&D vision, as we complete the evolution of
"I'm pleased to join
Dr. Namouni brings more than 20 years of oncology and cancer immunotherapy drug development expertise, as well as clinical experience as a pediatric oncologist. Prior to joining
About
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding expectations related to
Trademarks
Opdivo® and Yervoy® are registered trademarks of Bristol-Myers Squibb Company. All other trademarks and trade names in this press release are the property of
View original content to download multimedia:http://www.prnewswire.com/news-releases/blueprint-medicines-strengthens-leadership-with-appointment-of-fouad-namouni-md-as-president-research--development-301121433.html
SOURCE
Media contact, Jim Baker, 617-844-8236, media@blueprintmedicines.com; Investor contact, Kristin Hodous, 617-714-6674, ir@blueprintmedicines.com